Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 - Test2 - elhamkhani - TriplyDB

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

http://www.wikidata.org/entity/Q27675879

about

Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk Approaches to preventative and therapeutic HIV vaccines Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?Immune correlates of vaccine protection against HIV-1 acquisition Sieve analysis in HIV-1 vaccine efficacy trials Designing synthetic vaccines for HIV Antibody responses to envelope glycoproteins in HIV-1 infection HIV-1 neutralizing antibodies: understanding nature's pathways HIV-1 envelope glycoprotein structure Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection A global approach to HIV-1 vaccine development Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains Progress in HIV-1 vaccine development.New concepts in HIV-1 vaccine development A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239 Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel.Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Survivors Remorse: antibody-mediated protection against HIV-1.HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine.Lessons learned from human HIV vaccine trials.HIV-1 vaccines: challenges and new perspectives Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection Novel directions in HIV-1 vaccines revealed from clinical trials Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles Antibody repertoire deep sequencing reveals antigen-independent selection in maturing B cells V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

P2860

Q24598653-89BA0F5A-5823-4019-BB06-97C30EB12A27 Q26764851-2B0CE7AA-9371-4B26-A8D2-083A2A536BC2 Q26765043-600A1800-FA23-406D-A534-070535797D08 Q26778573-F6DFDF1B-1D39-41DC-8907-285AADBAE3CD Q26851376-360D841C-814D-409E-BCBA-39DD727C4609 Q26862617-9A0B2C4D-1CF4-44E7-83AD-084741000098 Q26991572-199054AD-D461-43D3-8A31-0D106FA4192E Q27000480-F394D7C6-C9D5-41CE-BC90-356F8AA90AF2 Q27011248-4A2B3709-B19D-47A4-84AD-06CFB9180876 Q27022652-BB0192F1-3E76-44C6-B93A-DE6EB64C6AA2 Q27024614-CD5E32B0-0281-49A7-8EC5-2CD2E7FFE910 Q27318508-0EF0BAE9-783C-4AB1-8CA5-E8FD4B797A9F Q27322403-1AB4267F-92A7-4871-A548-601C7A29213A Q27644501-072A5A36-6ACE-45C8-8644-CFEB9EA10689 Q27644634-3E89085F-FEBB-452B-8918-C20FED59C064 Q27680688-5BCFC82D-9CD6-4144-85DD-029F86A6D2C6 Q27681527-832E0A96-B9CF-44FD-87C8-C9FFEB535D41 Q27684503-A351EF70-3BF2-42D8-B446-7900751AE38A Q27693849-F9080984-0871-4C19-9943-D6C3D50A86D9 Q28067027-8826CDE2-0B49-4B95-B180-917975E3BDA9 Q28383579-88476A10-AB5A-40F5-92B6-258666712AA9 Q28830298-F17C695F-B23F-4EE1-88A0-7030907941C7 Q30152923-A494AEB5-FDBB-4F47-928E-C3C4D147E018 Q30234773-C0A8A770-E50E-40AC-BEE5-B993610033AE Q30238730-9E685E62-4A82-4F37-99B6-C2E83D82FCCC Q30355260-8E41F305-19F6-4E10-A9C8-DF5A52C51709 Q30375785-DFCD1B23-5C80-404C-910E-6069D58D643C Q30578618-E948A026-DF84-40D8-B1F2-22966B1D703E Q32183405-73FCE041-DDF2-4889-AB77-8063E7009381 Q33557844-799E4978-C88A-46B8-BE98-53CD14DB6F2E Q33577972-170B78A6-40BA-4B1E-BEAD-D29B5BC8993B Q33620546-ECBFA9E3-166D-493E-8174-C2EEF3D31031 Q33645528-35C38D7B-5F2B-482B-85EB-78CFBD7C0983 Q33742529-D9ABB999-C025-41DB-AC55-3939585EFD25 Q33743734-571117E2-9BE9-4CD5-A50E-4B88DDD29436 Q33804531-F010834A-7145-44F3-8725-F11E70A69833 Q33813145-86B6AA3D-5C72-4B95-8230-61794F3CC4B1 Q33835000-08E837CF-988F-4D0D-8C77-9CE30EBDA730 Q33874253-0561A3DB-B3E7-463A-89CE-6470564D8D3F Q33900395-1244F231-EE70-4BD7-A3AA-D8C3A6E72DBF

P2860

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

http://www.wikidata.org/entity/Q27675879

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Vaccine Induction of Antibodie ...... otein Variable Regions 1 and 2

@ast

Vaccine Induction of Antibodie ...... otein Variable Regions 1 and 2

@en

Vaccine Induction of Antibodie ...... otein Variable Regions 1 and 2

@nl

type

label

Vaccine Induction of Antibodie ...... otein Variable Regions 1 and 2

@ast

Vaccine Induction of Antibodie ...... otein Variable Regions 1 and 2

@en

Vaccine Induction of Antibodie ...... otein Variable Regions 1 and 2

@nl

prefLabel

Vaccine Induction of Antibodie ...... otein Variable Regions 1 and 2

@ast

Vaccine Induction of Antibodie ...... otein Variable Regions 1 and 2

@en

Vaccine Induction of Antibodie ...... otein Variable Regions 1 and 2

@nl

P1433

Q27675879-6C435109-526B-498E-AFAF-8710EDF44DA4

P1476

Q27675879-57977A25-7D80-43C0-B90F-94163F583B1A

P2093

Q27675879-052DE6E1-EC37-49AF-9B9A-120997A3FC54

Q27675879-083E6843-353D-4542-AF37-543C41E50D90

Q27675879-0F56D113-B7F1-400D-A590-E5E6436E7003

Q27675879-101C7D19-ACCC-4462-B19C-28F410EAD4E8

Q27675879-1212FB48-F978-4BF4-AB05-CBE550174558

Q27675879-180C1845-DC72-4E08-9837-1073834F45C6

Q27675879-1B1FBA6F-570A-4656-95E9-8D2A71E94797

Q27675879-2F6E2CC7-71D0-470E-B156-BEC63860E563

Q27675879-322A1DB8-8DF7-4587-995B-EFA982CC6E57

Q27675879-32C63CD7-4BC0-4F81-A55C-C5A310B0779B

P2860

Q27675879-10BB4A5B-936C-49DC-9E34-C16F4CCFA4AA

Q27675879-13D9B65A-11A6-4650-B3E4-7AA94076CA5B

Q27675879-16ED5EB9-186B-4C75-88DF-397F4A829238

Q27675879-190FA813-0324-4251-9DF6-A34253507291

Q27675879-1A36104F-DB24-49BB-A3D3-A8C7A7C72167

Q27675879-1C153F20-B499-4A28-B66C-0C6F21AA5A69

Q27675879-1E4F01C7-D7BB-4EAA-9272-334256B54C2D

Q27675879-20766616-AF30-4AB1-9370-79FDD762BFD0

Q27675879-26352C84-4A10-45E5-99BD-6AAAE7C4CDA5

Q27675879-26F7F178-04BA-4C53-85E0-F2CD5ECD62B1

P304

Q27675879-BC548FAE-1433-4CD5-8E68-BF5448E271A2

P31

Q27675879-8AE4E24D-9F70-414D-B5BD-270CD22A4881

P3181

Q27675879-969FA37A-1325-4929-97BB-CD4C9F228408

P356

Q27675879-BDAFB943-A092-45B2-90DF-E9619AB2EB8A

P407

Q27675879-8648E513-9120-46E6-92FF-A873D361C1A3

P433

Q27675879-03F22B3C-BB9B-44EB-8D53-8A24B0D5D440

P478

Q27675879-B69704FE-2B2E-4FAB-AD35-B2FE061AAE88

P50

Q27675879-04E4007E-CB8B-4EC4-9269-3847C6AA6B2B

Q27675879-1C4DA2CD-68CB-4442-B7C6-1FCAF3725C8B

Q27675879-1E6E43D5-15E0-4F83-A79F-45D1F09FDD7D

Q27675879-4FF5B7F7-C99D-4B6C-999A-C7268865906C

Q27675879-A974A3E2-03C2-4326-B390-7E4DAE65409F

Q27675879-AE791A24-0A95-4BC3-BCF2-D3D51BA83CED

Q27675879-B41478E1-A153-4612-AF91-F25854D6381C

Q27675879-C4F1FF20-A383-4C95-8B52-8A958B19B686

Q27675879-CD2CBA75-E705-4F4A-9CF8-F10642A3506B

Q27675879-EF99692D-AD88-44C6-82CF-682694F7A75C

P577

Q27675879-F5E75DD4-723C-4F18-A96F-45CFAE866107

P5875

Q27675879-211A0F82-FA78-4F66-999D-4DAF58905337

P698

Q27675879-8585245E-7FFD-4385-ACBF-47F55516214F

P921

Q27675879-A9A02F93-D974-47C7-A56D-AEA882C91E5D

P932

Q27675879-5CB64313-25A1-4ACB-8547-5F744986A6CB

P3181

P356

J.IMMUNI.2012.11.011

P1433

P1476

Vaccine Induction of Antibodie ...... otein Variable Regions 1 and 2

@en

P2093

Abraham Pinter

http://www.w3.org/2001/XMLSchema#string

Chun-Yen Tsao

http://www.w3.org/2001/XMLSchema#string

Daniel M Kozink

http://www.w3.org/2001/XMLSchema#string

Faruk Sinangil

http://www.w3.org/2001/XMLSchema#string

Georgia D Tomaras

http://www.w3.org/2001/XMLSchema#string

Hua-Xin Liao

http://www.w3.org/2001/XMLSchema#string

James Tartaglia

http://www.w3.org/2001/XMLSchema#string

Jason S McLellan

http://www.w3.org/2001/XMLSchema#string

Justin Pollara

http://www.w3.org/2001/XMLSchema#string

Kaifan Dai

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals

Coot: model-building tools for molecular graphics

Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7

PHENIX: building new software for automated crystallographic structure determination

High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses

ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

P304

176-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

244780

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.IMMUNI.2012.11.011

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

Jaranit Kaewkungwal

Thomas B. Kepler

David C Montefiori

P577

2013-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234122752

http://www.w3.org/2001/XMLSchema#string

P698

23313589

http://www.w3.org/2001/XMLSchema#string

P921

P932

3569735

http://www.w3.org/2001/XMLSchema#string